---
title: "Bronchogen"
canonical_url: https://peptidelibrary.app/library/bronchogen
description: "Short synthetic tetrapeptide marketed as a Khavinson bronchial/lung bioregulator. Papers give its sequence as Ala-Glu-Asp-Leu (AEDL) or Ala-Asp-Glu-Leu (ADEL). Russian literature only; not FDA-approved."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Bronchogen

Bronchogen (also called Lung bioregulator or AEDL) is a khavinson bioregulator. Bronchogen is a synthetic tetrapeptide, written Ala-Glu-Asp-Leu in most papers and Ala-Asp-Glu-Leu in some, in the Khavinson bioregulator series associated with bronchial and pulmonary tissue.

Short synthetic tetrapeptide marketed as a Khavinson bronchial/lung bioregulator. Papers give its sequence as Ala-Glu-Asp-Leu (AEDL) or Ala-Asp-Glu-Leu (ADEL). Russian literature only; not FDA-approved.

Also known as: Lung bioregulator, AEDL, ADEL.

Categories: Experimental.

## Classification

- Type: Khavinson bioregulator / research
- Mechanism class: Short Peptide Bioregulator
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Bronchogen is a synthetic tetrapeptide, written Ala-Glu-Asp-Leu in most papers and Ala-Asp-Glu-Leu in some, in the Khavinson bioregulator series associated with bronchial and pulmonary tissue. The proposed mechanism common to that series is that short peptides enter the cell nucleus and interact directly with specific promoter regions of DNA, altering transcription of tissue-relevant genes — a form of peptide-directed epigenetic regulation. Supporting work consists largely of cytogenetic and cell-culture studies published by one research group, predominantly in Russian-language journals. The mechanism has not been independently established in Western controlled research, and no clinical trials support the tissue-specific claims.

Targets: Bronchial epithelium (proposed).

Origin: Synthetic short peptide from the Khavinson bioregulator series.

## Properties

- Molecular formula: C18H30N4O9
- Molecular weight: 446.46 g/mol
- Half-life: Not established (small tripeptide)

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Lab & animal studies
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 2
- Latest source: 2015

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. Bull Exp Biol Med. 2015. 2015. Preclinical: animal or lab study. Population: Rats with lung disease induced by 60 days of intermittent nitrogen dioxide exposure. Less remodelling of the bronchial epithelium and lung tissue, more secretory IgA and less neutrophilic inflammation. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/26468022/)
2. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014. 2014. Preclinical: in vitro (cells or tissue). Population: Human embryonic bronchial epithelial cell cultures at the 1st, 7th and 14th passage. Changes in proliferation and differentiation proteins and genes, strongest in later-passage ("old") cultures; DNA binding shown in solution. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/25015171/)

## Safety

Side effects: Not characterized in modern RCTs.

Risks: Unregulated research products; Evidence quality is limited.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Bronchogen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is Bronchogen?

Short peptide marketed as a Khavinson bronchial/lung bioregulator (often AEDL). Russian literature only; not FDA-approved.

### How does Bronchogen work?

Bronchogen is Ala-Glu-Asp-Leu, a synthetic tetrapeptide in the Khavinson bioregulator series associated with bronchial and pulmonary tissue. The proposed mechanism common to that series is that short peptides enter the cell nucleus and interact directly with specific promoter regions of DNA, altering transcription of tissue-relevant genes — a form of peptide-directed epigenetic regulation.

### Is Bronchogen FDA approved?

No. Bronchogen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Bronchogen?

Reported half-life for Bronchogen is Not established (small tripeptide). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What peptides are similar to Bronchogen?

Compounds most often compared with Bronchogen include Bonomarlot, Cardiogen, Cartalax and Cerluten. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability — Bull Exp Biol Med, 2011](https://pubmed.ncbi.nlm.nih.gov/21240358/)
- [\[ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY\] — Ross Fiziol Zh Im I M Sechenova, 2017](https://pubmed.ncbi.nlm.nih.gov/30199201/)
- [Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum — Biochemistry (Mosc), 2017](https://pubmed.ncbi.nlm.nih.gov/28371610/)
- [Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology — Bull Exp Biol Med, 2015](https://pubmed.ncbi.nlm.nih.gov/26468022/)
- [Peptides tissue-specifically stimulate cell differentiation during their aging — Bull Exp Biol Med, 2012](https://pubmed.ncbi.nlm.nih.gov/22808515/)
